

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04 REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
POLICY NUMBER: 2.01.42 CATEGORY: Vaccines/Biologics	PAGE: 1 OF: 10

• If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
• Medical policies apply to commercial and Medicaid products only when a contract benefit for the specific service exists.
• Medical policies only apply to Medicare products when a contract benefit exists and where there are no National or Local Medicare coverage decisions for the specific service.

POLICY STATEMENT:

Childhood and adult immunizations are **eligible for coverage** when:

- I. administered according to the official recommendations of the Advisory Committee on Immunization Practices (ACIP) to the Centers for Disease Control and Prevention (CDC), and
- II. the services are covered by a member's contract/benefit design.

ACIP recommendations are effective on the date of the ACIP meeting at which the recommendations were made and are considered official when publicized by the CDC.

POLICY GUIDELINES:

- I. Refer to the member's subscriber contract and/or the Customer (Member/Provider) Service Department for specific contract age limitations for dependents.
- II. Coverage criteria are adjusted when national guidelines are revised to address new vaccines or changes in vaccine indications or the CDC makes recommendations for changes in administration schedules related to national vaccine shortages.
- III. Coverage for vaccines related to or required only as a condition of work, travel or school are strictly contract dependent.

DESCRIPTION:

Immunization is the process of stimulating the body's immune system to protect against a specific infection. Minute amounts of the specific bacteria or virus, in whole or part, are specially treated so that when given to the patient, they will stimulate the body's immune system without actually causing disease. Some immunizations require "boosters," or repeat doses of the same vaccine, to keep up the body's protection against a specific bacteria or virus.

Recommended Pediatric and Adult immunizations are addressed as part of the Health Plan's Preventive Health Guidelines.

The "Recommended Childhood Immunization Schedule" that is part of Preventive Health Services: Healthy Children to Age 19 guidelines is produced by the American Academy of Pediatrics (AAP), the ACIP of the CDC, and the American Academy of Family Physicians and can be referenced at: <https://www.excellusbcbs.com/wps/portal/xl/prv/pc/cpg>. The Childhood & Adolescent Immunization Schedules are also available at: <http://www.cdc.gov/vaccines/>.

The following immunizations are included in the recommendations:

• Diphtheria-Tetanus-Pertussis	• Influenza A (Novel H1N1, Swine)	• Pneumococcal
• Hepatitis A	• Influenza (Seasonal)	• Polio
• Hepatitis B	• Measles, Mumps, Rubella	• Rotavirus
• Haemophilus Influenza Type B (HiB)	• Meningococcal	• Varicella
• Human Papilloma virus (HPV) (Cervarix [HPV2], Gardasil [HPV4])		

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04
POLICY NUMBER: 2.01.42	REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
CATEGORY: Vaccines/Biologics	PAGE: 2 OF: 10

The Preventive Care of Adults Ages 19 Years and Older guidelines include immunization schedules and information for both persons at “usual risk” and “at risk”. These guidelines are based primarily on recommendations from the Report of the US Preventive Services Task Force and the Department of Health and Human Services Centers for Disease Control and Prevention Recommended Adult Immunization Schedule and can be referenced at:

<https://www.excellusbcbs.com/wps/portal/xl/prv/pc/cpg>. The Adult Immunization Recommendations Schedule is also available at: <http://www.cdc.gov/vaccines/>.

The following immunizations are included in the recommendations:

- Diphtheria-Tetanus-Pertussis
- Hepatitis A
- Hepatitis B
- Human Papilloma virus (HPV) (Cervarix [HPV2], Gardasil [HPV4])
- Influenza A (Novel H1N1, Swine)
- Influenza (Seasonal)
- Measles, Mumps, Rubella
- Meningococcal
- Pneumococcal
- Varicella
- Varicella Zoster (Shingles)

According to New York State Law, every health insurance policy providing medical, major medical or similar comprehensive type coverage must provide coverage for necessary immunizations as recommended by the Advisory Committee on Immunization Practices (ACIP) to the CDC.

CODES: Number Description

Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

CPT:	90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered
	90461	each additional vaccine or toxoid component administered
90630 (E/I)		Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use (<i>effective 1/1/15, pending FDA approval</i>)
90632		Hepatitis A vaccine, adult dosage, for intramuscular use
90633		Hepatitis A vaccine, pediatric/adolescent dosage-2 dose schedule, for intramuscular use
90634		Hepatitis A vaccine, pediatric/adolescent dosage-3dose schedule, for intramuscular use
90636		Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use
90644		Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza b vaccine, tetanus toxoid conjugate (Hib-MenCY-TT), 4 dose schedule, when administered to children 2 - 15 months of age, for intramuscular use
90645		Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use
90646		Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, for intramuscular use
90647		Hemophilus influenza b vaccine (Hib), PRP-OMP conjugate (3 dose schedule), for intramuscular use
90648		Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4 dose schedule), for intramuscular use

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04
POLICY NUMBER: 2.01.42	REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
CATEGORY: Vaccines/Biologics	PAGE: 3 OF: 10

90649 Human Papilloma virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use

90651 (E/I) Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (HPV), 3 dose schedule, for intramuscular use (*effective 1/1/15, pending FDA approval*)

90650 Human Papilloma virus (HPV) vaccine, types 16 and 18, bivalent, 3 dose schedule, for intramuscular use

90653 (E/I) Influenza virus vaccine, inactivated, subunit, adjuvanted, for intramuscular use (*pending FDA approval*)

90654 Influenza virus vaccine, split virus, preservative free, for intradermal use

90655 Influenza virus vaccine, trivalent, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use

90656 Influenza virus vaccine, trivalent, split virus, preservative free, when administered to 3 years of age and older, for intramuscular

90657 Influenza virus vaccine, trivalent, split virus, when administered to children 6-35 months of age, for intramuscular use

90658 Influenza virus vaccine, trivalent, split virus, when administered to 3 years of age and older, for intramuscular use

90660 Influenza virus vaccine, trivalent, live, for intranasal use

90661 Influenza virus vaccine, derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use

90662 Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use

90664 (E/I) Influenza virus vaccine, pandemic formulation, live, for intranasal use (*pending FDA approval*)

90666 (E/I) Influenza virus vaccine, pandemic formulation, split virus, preservative free, for intramuscular use (*pending FDA approval*)

90667 (E/I) Influenza virus vaccine, pandemic formulation, split virus, adjuvanted, for intramuscular use (*pending FDA approval*)

90668 (E/I) Influenza virus vaccine, pandemic formulation, split virus, for intramuscular use (*pending FDA approval*)

90669 Pneumococcal conjugate vaccine, 7 valent, for intramuscular use

90670 Pneumococcal conjugate vaccine, 13 valent, for intramuscular use

90672 Influenza virus vaccine, quadrivalent, live, for intranasal use

90673 Influenza virus vaccine, trivalent, derived from recombinant DNA (RIV3), hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use

90680 Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use

90681 Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use

90685 Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04
POLICY NUMBER: 2.01.42	REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
CATEGORY: Vaccines/Biologics	PAGE: 4 OF: 10

90686 Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to individuals 3 years of age or older, for intramuscular use

90687 Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use

90688 Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age or older, for intramuscular use

90696 Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4 years through 6 years of age, for intramuscular use

90697 (E/I) Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-HibHepB), for intramuscular use (*effective 1/1/15, pending FDA approval*)

90698 Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated (DTaP-Hib-IPV), for intramuscular use

90700 Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use

90702 Diphtheria and tetanus toxoids (DT), adsorbed when administered to individuals younger than 7 years, for intramuscular use

90703 Tetanus toxoid adsorbed, for intramuscular use

90704 Mumps virus vaccine, live, for subcutaneous use

90705 Measles virus vaccine, live, for subcutaneous use

90706 Rubella virus vaccine, live, for subcutaneous use

90707 Measles, mumps, and rubella vaccine (MMR), live, for subcutaneous use

90708 Measles and rubella virus vaccine, live, for subcutaneous use

90710 Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use

90712 Poliovirus vaccine, (any type[s]) (OPV), live, for oral use

90713 Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use

90714 Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to individuals 7 years or older, for intramuscular use

90715 Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use

90716 Varicella virus vaccine, live for subcutaneous use

90719 Diphtheria toxoid, for intramuscular use

90720 Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use

90721 Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DtaP-Hib), for intramuscular use

90723 Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04
POLICY NUMBER: 2.01.42	REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
CATEGORY: Vaccines/Biologics	PAGE: 5 OF: 10

90732 Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use

90733 Meningococcal polysaccharide vaccine (any groups(s)), for subcutaneous use

90734 Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent), for intramuscular use

90735 Japanese encephalitis virus vaccine, inactivated, for subcutaneous use

90736 Zoster (shingles) vaccine, live, for subcutaneous injection

90738 Japanese encephalitis virus vaccine, inactivated, for intramuscular use

90739 (E/I) Hepatitis B vaccine, adult dosage (2 dose schedule), for intramuscular use (*pending FDA approval*)

90740 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose schedule), for intramuscular use

90743 Hepatitis B vaccine, adolescent (2 dose schedule), for intramuscular use

90744 Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), for intramuscular use

90746 Hepatitis B vaccine, adult dosage, (3 dose schedule), for intramuscular use

90747 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use

90748 Hepatitis B and Hemophilus influenza b vaccine (HepB-Hib), for intramuscular use

Copyright © 2014 American Medical Association, Chicago, IL

HCPCS:

- G0008 Administration of influenza virus vaccine
- Q2034 Influenza virus vaccine, split virus, for intramuscular use (Agriflu) Sipuleucel-t, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukopheresis and all other preparatory procedures, per infusion
- Q2035 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA)
- Q2036 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL)
- Q2037 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLUVIRIN)
- Q2038 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)
- Q2039 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified)
- S0195 Pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five to nine years of age who have not previously received the vaccine

ICD9: Numerous

ICD10: Numerous

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04
POLICY NUMBER: 2.01.42	REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
CATEGORY: Vaccines/Biologics	PAGE: 6 OF: 10

REFERENCES:

American Academy of Pediatrics. 2014 Immunization schedules. Last updated 2/4/14. [http://www2.aap.org/immunization/IZSchedule.html] accessed 6/10/14.

American Academy of Pediatrics. Immunization. Last updated 6/9/14 [http://www2.aap.org/immunization/index.html] accessed 6/10/14.

American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2013-2014. Policy statement. *Pediatrics* 2013 Oct;132(4):1-16.

American Academy of Pediatrics Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. *Pediatrics* 2011 Dec;128(6):1213-8.

American Academy of Pediatrics Committee on Infectious Diseases. Poliovirus. *Pediatrics* 2011 Oct;128(4):805-8.

American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. *Pediatrics* 2009 May;123(5):1412-20.

American Academy of Pediatrics Committee on Infectious Diseases. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. *Pediatrics* 2011 Sep;128(3):630-2.

American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2012-2013. *Pediatrics* 2012 Oct;130(4):780-92.

American Academy of Pediatrics. Red Book Online: Vaccine status table. Updated 2/20/14 [http://aapredbook.aappublications.org/site/news/vaccstatus.xhtml] accessed 6/10/14.

American College of Obstetricians and Gynecologists. Committee on Adolescent Health; Immunization Expert Work Group of the American College of Obstetricians and Gynecologists. Committee opinion no. 588: human papillomavirus vaccination. *Obstet Gynecol* 2014 Mar;123(3):712-8.

American College of Obstetricians and Gynecologists. Committee Opinion No. 468. Influenza vaccination during pregnancy. *Obstet Gynecol* 2010 Oct;116(4):1006-7.

American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 566: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. *Obstet Gynecol* 2013 Jun;121(6):1411-4.

Baxter R, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. *Pediatr Infect Dis J* 2011 Mar;30(3):e41-8.

Centers for Disease Control and Prevention (CDC). Addition of severe combine immunodeficiency as a contraindication for administration of rotavirus vaccine. *MMWR* 2010 Jun 11;59(22):687-8.

Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years --United States, 2014. *MMWR Surveill Summ* 2014 Feb 7;63(05):108-9 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6305a6.htm?s_cid=mm6305a6_w] accessed 6/10/14.

Centers for Disease Control and Prevention (CDC). ACIP Adult Immunization Work Group, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2014. *MMWR Surveill Summ* 2014 Feb 7;63(05):110-12 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6305a7.htm?s_cid=mm6305a7_w] accessed 6/10/14.

Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human Papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2010 May 28;59(20):626-9.

SUBJECT: IMMUNIZATIONS POLICY NUMBER: 2.01.42 CATEGORY: Vaccines/Biologics	EFFECTIVE DATE: 09/16/04 REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14 PAGE: 7 OF: 10
-----------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Centers for Disease Control and Prevention (CDC). Hepatitis A vaccination coverage among children aged 24 – 35 months --- United States, 2006 and 2007. MMWR 2009 Jul 3;58(25):689-94.

*Centers for Disease Control and Prevention (CDC). Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR 2008 Oct 3;57(39):1079-80.

*Centers for Disease Control and Prevention (CDC). Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR 2008 Oct 3;57(39):1078-9.

Centers for Disease Control and Prevention (CDC). Briere EC, et al; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2014 Feb 28;63(RR-01):1-14.

Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices – United States, 2013-2014. MMWR Morb Mortal Wkly Rep 2013 Sep 20;62(7):1-43.

Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011 Oct 14;60(40):1391-2.

Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011 Dec 23;60(50):1705-8.

Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2013*. Ann Intern Med 2013 Feb 5;158(3):191-9.

Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010 Sep 3;59(34):1102-6.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of haemophilus influenzae Type b (Hib) Vaccine: reinstatement of the booster dose at ages 12—15 months. MMWR 2009 Jun 26;58(24):673-4.

Centers for Disease Control and Prevention (CDC). Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR 2009 Aug 7;58(30):829-30.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011 Oct 21;60(41):1424-6.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013 Feb 22;62(7):131-5.

[<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm>] accessed 6/10/14.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012 Jun 29;61(25):468-70. Erratum in: MMWR Morb Mortal Wkly Rep 2012 Jul 13;61(27):515.

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6125a4.htm?s_cid=mm6125a4_e] accessed 6/10/14.

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04
POLICY NUMBER: 2.01.42	REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
CATEGORY: Vaccines/Biologics	PAGE: 8 OF: 10

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep 2013 Jul 19;62(28):574-6.

Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR 2010 May 7;59(RR-3) [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5922a3.htm?s_cid=mm5922a3_w] accessed 6/10/14.

Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011 Dec 23;60(50):1709-11. [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a4.htm] accessed 6/10/14.

Centers for Disease Control and Prevention (CDC). Use of Influenza A (H1N1) 2009 monovalent vaccine. Recommendation of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2009 Aug 21;58(Early release):1-8 [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm?s_cid=rr58e0821a1e] accessed 6/10/14.

Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013 Jun 28;62(25):521-4.

Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR Morb Mortal Wkly Rep 2013 Nov 15;62(45):898-900.

Centers for Disease Control and Prevention (CDC). Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep 2014 Jun 20;63(24):527-30 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6324a2.htm?s_cid=mm6324a2_e] accessed 6/19/14.

Centers for Disease Control and Prevention. Vaccines and preventable diseases: seasonal influenza (flu) vaccination. Last modified 2013 Sep 25 [http://www.cdc.gov/vaccines/vpd-vac/flu/default.htm] accessed 6/10/14.

Centers for Disease Control and Prevention (CDC). Vaccines and immunizations: immunization schedules. Last modified 2014 Jan 31 [http://www.cdc.gov/vaccines/schedules/index.html] accessed 6/10/14.

*Chang CC, et al. Influenza vaccine for children and adults with bronchiectasis. *Cochrane Database Syst Rev* 2007 Jul 18;(3):CD006218.

Clark TW, et al. Trial of Influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine – preliminary report. NEJM Online First 2009 Sep 10 [http://content.nejm.org/cgi/content/full/NEJMoa0907650?query=TOC] accessed 9/11/09.

Cohn AC, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013 Mar 22;62(RR-2):1-28. [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm] accessed 6/10/14.

Cortese MM, et al. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009 Feb 6;58(RR-2):1-25.

*Demicheli V, et al. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev*. 2004;(3):CD001269.

*Foerster V and Murtagh J. Human papillomavirus (HPV) vaccines: A Canadian update. Issues in emerging health technologies. Issue 109. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.

Givon-Lavi N, et al. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J 2010 Aug;29(8):756-62.

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04
POLICY NUMBER: 2.01.42	REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
CATEGORY: Vaccines/Biologics	PAGE: 9 OF: 10

Greenberg ME, et al. Response after one dose of a monovalent Influenza A (H1N1) 2009 vaccine – preliminary report. NEJM Online First 2009 Sep 10 [<http://content.nejm.org/cgi/content/full/NEJMoa0907413?query=TOC>] accessed 9/11/09.

Hancock K, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 Influenza virus. NEJM Online First 2009 Sep 10 [<http://content.nejm.org/cgi/content/full/NEJMoa0906453?query=TOC>] accessed 9/11/09.

Jacobson RM. An update on childhood and adolescent vaccines. Mayo Clin Proc 2009 May;84(5):457-9; quiz 460.

*Jefferson TO, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007;(2):CD001269.

*Kroger AT, et al. General recommendations on immunization. MMWR 2006 Dec 1;55(RR15):1-48.

Ladhani S, et al. Recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease. J Infect 2009 Jan;58(1):3-14.

Langley JM, et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine 2011 Feb 24;29(10):1921-8.

Lazarus R, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011 Mar;52(6):736-42.

*Markowitz LE, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 Mar 23;56(RR-2):1-24.

Marin M, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010 May 7;59(RR-3):1-12.

National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011 Jan 28;60(2):1-64.

Pickering LK, et al. Immunization programs for infants, children, adolescents and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009 Sep 15;49:817-40.

Rodriguez AC, et al. Longitudinal study of Human Papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. JNCI 2010 Mar 2;102(5):315-24.

State of New York Department of Financial Services. Coverage for preventive and primary care services. Statutory Reference: New York Insurance Law Sections 3216(i)(17), 3221(l)(8) and 4303(j). [http://www.dfs.ny.gov/insurance/circltr/2006/cl06_13.htm] accessed 6/10/14.

Thierry-Carstensen B, et al. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. Vaccine 2012 Aug 10;30(37):5464-71.

U. S. Food and Drug Administration. Vaccines, Blood and Biologics. Complete list of vaccines licensed for immunization and distribution in the US. Last updated: 2013 Jun 11 [<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>] accessed 6/12/13.

* key article

KEY WORDS:

Immunizations, vaccines.

SUBJECT: IMMUNIZATIONS	EFFECTIVE DATE: 09/16/04
POLICY NUMBER: 2.01.42	REVISED DATE: 10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14
CATEGORY: Vaccines/Biologics	PAGE: 10 OF: 10

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There currently is neither a National Coverage Determination (NCD) nor a Local Coverage Determination (LCD) for Immunizations. However, immunizations are addressed in the Medicare Benefit Policy Manual, Chapter 15 – Covered Medical and Other Health Services, Section 50.4.4.2. Please refer to the following website for Medicare Members: <http://www.cms.hhs.gov/manuals/Downloads/bp102c15.pdf>.